Dr Anna Minchom (The Royal Marsden Hospital, London, UK), Prof Natasha Leighl (Princess Margaret Cancer Centre, Toronto, Canada), Dr Victor Moreno (Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain) and Dr Carlos Cabrera (UOMi Cancer Center, Barcelona, Spain) discuss the updates on EGFR mutated advanced NSCLC from ESMO 2021.
Dr Minchom gives an introduction to EGFR-mutated NSCLC, before Prof Leighl and Dr Cabrera discuss drugs in secondary osimertinib resistance. They mention the analysis from the CHRYSALIS study and the preliminary results from CHRYSALIS-2 study. Dr Minchom then discusses the first-line combo studies with EGFR TKI-angiogenic drugs with Dr Moreno and Prof Leighl. Dr Cabrera also talks about the ORCHARD study and the effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases. They further discuss the Beverly trial and other recent data from ESMO 2021. They conclude by covering some studies regarding the testing for EGFR mutation/ resistance mechanisms.
|Analysis from the CHRYSALIS study|
|PPreliminary results from the CHRYSALIS-2 study|
|Mechanisms of resistance in EGFR adv NSCLC|
|Targeted therapies for EGFR adv NSCLC|
|Toxicity profiles for targeted therapies|
|ORCHARD study and the effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated NSCLC with brain metastases|
|Combo studies with EGFR TKI-angiogenic drugs|
|What to do if a patient progresses?|
|Discussion on biomarker testing data from ESMO 2021|
This programme is supported by an unrestricted educational grant from Janssen.